Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

University Hospitals (UH)

Status: Completed

Conditions: Erectile Dysfunction; BPH

Treatments: Drug: Alfuzosin 10 mg

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00256399

L-9835

Details and patient eligibility

About

Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.

Full description

The study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for 90 days. The total duration of the study will be 120 days.

Enrollment: 6 patients

Sex: Male

Ages: 45 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males 45-75 years of age
• Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED
• Men with steady partner and who agree to attempt sex once a week.

Exclusion criteria

• Prostate cancer
• Prostatitis
• Penile disease
• Cardiac co-morbidity
• Pre-existing co-morbid conditions
• History of sensitivity to the drug or similar drugs
• Enrollment in another clinical trial
• Impaired hepatic function
• Impaired renal function
• Mental conditions rendering subject unable to understand the study
• Subjects not likely to comply with protocol

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)